Please participate in a brief survey, your insights are invaluable in helping to understand current practices, identify areas of variation, and inform future guidelines.
redcap.petermac.org.au/surveys/?s=P...

Challenging CMV Cases in Solid Organ Transplant Recipients
Wednesday 15 October 2025
6.00pm - 7.30pm

Presenters:

Helen Tang (RPAH)

Jenny Li (Alfred)

Becky Lane (ADHB)

To register click asidevents.eventsair.com/cmv-webinars....

ASID is hosting two webinars on CMV thanks to the support of Takeda Educational Grant.

Challenging CMV Cases in Hematologic Stem Cell Transplant Recipients and Patients with Hematologic Malignancies

Wednesday 17 September
6.00pm - 7.30pm

To register - asidevents.eventsair.com/cmv-webinars...

Innovation in active and passive immunisation of people who are immunocompromised: a call to action The proportion of the population with immunocompromising conditions, who are at increased risk for complications from infectious diseases, continues to grow. Concurrently, outbreaks due to known and e...

Paper 2-Innovation in active and passive immunisation of people who are immunocompromised: a call to action

www.thelancet.com/journals/lan...

Innovation in active and passive immunisation of people who are immunocompromised: a call to action The proportion of the population with immunocompromising conditions, who are at increased risk for complications from infectious diseases, continues to grow. Concurrently, outbreaks due to known and e...

More critical than ever - @ncicancer.bsky.social @petermaccc.bsky.social
#TxID

Innovation in active and passive immunisation of people who are immunocompromised: a call to action - The Lancet Infectious Diseases www.thelancet.com/journals/lan...

Delighted to have been part of these important ECiL-10 c diff guidelines specific to our haematology patients.
#TxID @ncicancer.bsky.social @ichs-global.bsky.social @theebmt.bsky.social

www.sciencedirect.com/science/arti...

Huge thanks to haem cancer consumers for guiding us on how to improve delivery of vaccination. Uptake is key! #TxID @ncicancer.bsky.social
url.au.m.mimecastprotect.com/s/R9OxCK1qwB...

Great work by @victoriahall.bsky.social @ncicancer.bsky.social

Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial In an in-depth immunological analysis of alternate influenza vaccination strategies in high-risk patients receiving therapy for hematological malignancy, p

Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial url: academic.oup.com/jid/article-...

The national update on vaccination in immunocompromised is out! Delighted to have contributed to this. #TxID

Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy Cytomegalovirus (CMV) reactivation occurred in 27% of CMV-seropositive chimeric antigen receptor–modified T-cell immunotherapy (CARTx) recipients within 12

I am sure he is too humble to mention his work which was one of the top papers of 2024 for me!

It was very lovely of @joshhillmd.bsky.social to highlight our trial in his top 10 papers at #escmidglobal
www.nejm.org/doi/abs/10.1...

We are excited for #ESCMIDGLOBAL - the premier event for Infectious Diseases and Microbiology hosted by @escmid.bsky.social in Vienna, Austria! 🌍
If you're planning to attend, we’d love to connect with you. Below are the details of our presentations, including titles, times, and locations.

It was a fantastic overview of the field and the need for more research!

Honoured to speak & present our @ncicancer.bsky.social work on infection prevention in cancer/transplant at the Australasian Society of ID ASM with @nikhil-singh.bsky.social @michyong.bsky.social @benwteh.bsky.social, & amazing to hear & see the incredible work done at other centres nationally 👏🏽

Vaccines for Use in Special Populations: Immunocompromised Hosts The proportion of immunocompromised individuals in the United States has grown rapidly and currently accounts for 6.6% of the US population [1]. Individual

Vaccines are critical for the protection of patients from infection - it was an honor to write this piece discussing the challenges and data needs for use in immunocompromised patients.

academic.oup.com/jid/article/...

Join us at the 15th Febrile Neutropenia Symposium, taking place online on March 15–16, 2025!

NCIC Researcher, @benwteh.bsky.social, will present on 'Standardised Reporting of Infection Events in Immunocompromised Patients.'

To learn more and sign up: cdn.wildapricot.com/24830/resour...

“It's a risk-benefit analysis”: Qualitative perspectives on barriers and enablers to post-treatment vaccination from adults affected by a haematological malignancy in Australia People affected by haematological malignancies are at high risk of morbidity and mortality caused by vaccine-preventable infections. However, vaccinat…

What drives or discourages our haematology patients from getting vaccinated. Lovely collab with HSR team @petermaccc.bsky.social

www.sciencedirect.com/science/arti...
#TxID #HaemOncID

We need anyone interested in reviewing for the journal to use this survey to submit interest. This will help us better tailor papers we send to you for review! Even if you are already reviewing for us, would encourage you to submit your preference. #IDSky

Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.

In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines. Read the full trial results: nej.md/40ztLNF

#MedSky #IDSky #Oncology

Fantastic effort Tori!

Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.

Very proud of this hard work & team effort from all involved! Limited benefit of adjuvanted flu 💉 & 2 vs 1 dose in pts w/ MM, CLL or NHL. @ncicancer.bsky.social @petermaccc.bsky.social @benwteh.bsky.social @trubianojason.bsky.social @michyong.bsky.social @nejm.org www.nejm.org/doi/full/10....

Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.

Practice affirming results from our team @victoriahall.bsky.social @ncicancer.bsky.social - No additional benefit from second influenza vaccine dose/adjuvant vaccines in non-HCT haematology patients. #TxID #IDsky #medsky

www.nejm.org/doi/full/10....

Thanks Steve - looking forward to working with you and the team!

Delighted to be part of the team and looking forward to advancing haem
Onc/TxID research!

Glucocorticoid dosing and implications for vaccination: Evolution of global definitions Despite widespread adoption of “high-dose” glucocorticoid definitions across international immunisation guidelines (i.e., prednisone-equivalent dosing >20 mg/day, or >2 mg/kg/day in children), the rationale remains unclear. Literature searches were performed through academic databases for this narrative review to identify relevant evidence regarding glucocorticoid dosing on vaccine responses and safety.

Glucocorticoid dosing and implications for vaccination: Evolution of global definitions

✅ Just Accepted
#IDSky